Groupe la Francaise Increases Holdings in Merck & Co., Inc. $MRK

Key Points

• Groupe la Francaise increased its Merck stake by 56.8% in the first quarter, ending the period with 73,551 shares valued at approximately $8.84 million. Institutional investors collectively own 76.07% of Merck’s stock.
• Analyst sentiment remains favorable, with 13 Buy ratings and seven Holds producing a consensus “Moderate Buy” rating and an average price target of $134.50. Barclays, UBS, and Bank of America recently raised their price targets.
• Merck exceeded quarterly revenue and EPS expectations, while declaring a quarterly dividend of $0.85 per share, equivalent to $3.40 annually and a yield of about 2.6%. Near-term sentiment may still be affected by acquisition costs and challenges in Gardasil demand.

Groupe la Francaise lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 56.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,551 shares of the company's stock after purchasing an additional 26,631 shares during the period. Groupe la Francaise's holdings in Merck & Co., Inc. were worth $8,840,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. during the fourth quarter valued at $26,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. in the fourth quarter worth $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $31,000. Finally, High Note Wealth LLC lifted its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after buying an additional 109 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRK. Barclays increased their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Wednesday. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research report on Friday, May 15th. UBS Group lifted their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Finally, Bank of America boosted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $134.50.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $129.95 on Friday. The firm has a market capitalization of $320.96 billion, a P/E ratio of 36.61, a PEG ratio of 5.17 and a beta of 0.19. Merck & Co., Inc. has a one year low of $77.53 and a one year high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The business has a fifty day moving average price of $123.02 and a 200-day moving average price of $118.37.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target on Merck from $140 to $150 and maintained an “overweight” rating, implying meaningful potential upside from recent trading levels. Barclays raises Merck price target
• Positive Sentiment: Erste Group modestly increased its fiscal 2027 EPS forecast to $9.54 from $9.52, signaling slightly stronger expectations for Merck’s longer-term earnings power. Erste Group raises Merck EPS estimate
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend supports the stock’s income appeal and represents an annualized yield of approximately 2.7%. Merck announces fourth-quarter dividend
• Positive Sentiment: A Merck-Wellcome joint venture is preparing doses of an experimental Ebola vaccine for clinical trials, providing a potential public-health and pipeline opportunity, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Analysts expect second-quarter revenue of about $16.33 billion and a loss of $0.26 per share, with acquisition-related costs, Keytruda performance, and Gardasil demand likely to determine whether results beat or miss expectations. Merck second-quarter earnings preview
• Neutral Sentiment: Valuation analysis finds Merck attractive on discounted cash flow and cash-flow measures but more fairly valued based on earnings, suggesting further gains will require continued fundamental execution. Merck valuation analysis
• Negative Sentiment: Near-term uncertainty ahead of earnings—including acquisition costs and ongoing Gardasil challenges—may be weighing on sentiment despite expected strength from Keytruda. Merck earnings metrics preview

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.